HRP20110097T1 - Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora - Google Patents
Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora Download PDFInfo
- Publication number
- HRP20110097T1 HRP20110097T1 HR20110097T HRP20110097T HRP20110097T1 HR P20110097 T1 HRP20110097 T1 HR P20110097T1 HR 20110097 T HR20110097 T HR 20110097T HR P20110097 T HRP20110097 T HR P20110097T HR P20110097 T1 HRP20110097 T1 HR P20110097T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- compound
- fluorophenyl
- solvate
- methyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 150000008048 phenylpyrazoles Chemical class 0.000 title 1
- 230000003637 steroidlike Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 54
- 150000003839 salts Chemical class 0.000 claims abstract 37
- 239000012453 solvate Substances 0.000 claims abstract 36
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 11
- 239000011737 fluorine Substances 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 9
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 8
- 239000000460 chlorine Substances 0.000 claims abstract 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract 3
- 150000002431 hydrogen Chemical class 0.000 claims abstract 3
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- UESOWOAVEKAWIK-UHFFFAOYSA-N 5-amino-n-[2-[[(2,6-dichlorobenzoyl)amino]methyl]-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NCC(O)(CNC(=O)C=2C(=CC=CC=2Cl)Cl)C(F)(F)F)C=NN1C1=CC=C(F)C=C1 UESOWOAVEKAWIK-UHFFFAOYSA-N 0.000 claims 7
- PEUFWNJXEBOKMU-UHFFFAOYSA-N 5-amino-n-[2-[[(2,6-difluorobenzoyl)-ethylamino]methyl]-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)pyrazole-4-carboxamide Chemical compound FC=1C=CC=C(F)C=1C(=O)N(CC)CC(O)(C(F)(F)F)CNC(=O)C(=C1N)C=NN1C1=CC=C(F)C=C1 PEUFWNJXEBOKMU-UHFFFAOYSA-N 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 210000000653 nervous system Anatomy 0.000 claims 4
- 208000000288 neurosarcoidosis Diseases 0.000 claims 4
- FVCBWLLKSKXYKF-UHFFFAOYSA-N 5-amino-n-[2-[[(2-bromo-6-fluorobenzoyl)amino]methyl]-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NCC(O)(CNC(=O)C=2C(=CC=CC=2F)Br)C(F)(F)F)C=NN1C1=CC=C(F)C=C1 FVCBWLLKSKXYKF-UHFFFAOYSA-N 0.000 claims 3
- LLZQGHOXJGIFKU-UHFFFAOYSA-N 5-amino-n-[2-[[(2-chloro-6-fluorobenzoyl)amino]methyl]-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NCC(O)(CNC(=O)C=2C(=CC=CC=2F)Cl)C(F)(F)F)C=NN1C1=CC=C(F)C=C1 LLZQGHOXJGIFKU-UHFFFAOYSA-N 0.000 claims 3
- VQMWEBFSNROOMJ-UHFFFAOYSA-N 5-amino-n-[2-[[[2,6-bis(difluoromethyl)benzoyl]amino]methyl]-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NCC(O)(CNC(=O)C=2C(=CC=CC=2C(F)F)C(F)F)C(F)(F)F)C=NN1C1=CC=C(F)C=C1 VQMWEBFSNROOMJ-UHFFFAOYSA-N 0.000 claims 3
- XLNTUXPQKFYPSZ-UHFFFAOYSA-N 5-amino-n-[2-[[[2-(difluoromethoxy)-6-fluorobenzoyl]amino]methyl]-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NCC(O)(CNC(=O)C=2C(=CC=CC=2F)OC(F)F)C(F)(F)F)C=NN1C1=CC=C(F)C=C1 XLNTUXPQKFYPSZ-UHFFFAOYSA-N 0.000 claims 3
- SZLNXROTOODREX-UHFFFAOYSA-N 5-amino-n-[2-[[[2-chloro-6-(difluoromethoxy)benzoyl]amino]methyl]-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NCC(O)(CNC(=O)C=2C(=CC=CC=2Cl)OC(F)F)C(F)(F)F)C=NN1C1=CC=C(F)C=C1 SZLNXROTOODREX-UHFFFAOYSA-N 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 206010027654 Allergic conditions Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010015943 Eye inflammation Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 201000009053 Neurodermatitis Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 239000002585 base Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0611587.7A GB0611587D0 (en) | 2006-06-12 | 2006-06-12 | Novel compounds |
| GB0625457A GB0625457D0 (en) | 2006-12-20 | 2006-12-20 | Novel compounds |
| GB0710217A GB0710217D0 (en) | 2007-05-29 | 2007-05-29 | Novel compounds |
| PCT/EP2007/055724 WO2007144327A2 (fr) | 2006-06-12 | 2007-06-11 | Nouveaux composés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110097T1 true HRP20110097T1 (hr) | 2011-03-31 |
Family
ID=38659745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110097T HRP20110097T1 (hr) | 2006-06-12 | 2011-02-08 | Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8247377B2 (fr) |
| EP (1) | EP2029549B1 (fr) |
| JP (1) | JP5497433B2 (fr) |
| KR (1) | KR101411276B1 (fr) |
| CN (1) | CN101501003B (fr) |
| AR (1) | AR061341A1 (fr) |
| AT (1) | ATE487703T1 (fr) |
| AU (1) | AU2007260067B2 (fr) |
| BR (1) | BRPI0713755A8 (fr) |
| CA (1) | CA2659564C (fr) |
| CR (1) | CR10489A (fr) |
| CY (1) | CY1111454T1 (fr) |
| DE (1) | DE602007010456D1 (fr) |
| DK (1) | DK2029549T3 (fr) |
| EA (1) | EA015540B1 (fr) |
| ES (1) | ES2355165T3 (fr) |
| GB (1) | GB0611587D0 (fr) |
| HK (1) | HK1127609A1 (fr) |
| HR (1) | HRP20110097T1 (fr) |
| IL (1) | IL195492A0 (fr) |
| MA (1) | MA30514B1 (fr) |
| MX (1) | MX2008015977A (fr) |
| NO (1) | NO20085100L (fr) |
| PL (1) | PL2029549T3 (fr) |
| PT (1) | PT2029549E (fr) |
| SI (1) | SI2029549T1 (fr) |
| TW (1) | TW200815360A (fr) |
| WO (1) | WO2007144327A2 (fr) |
| ZA (1) | ZA200810161B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0611587D0 (en) * | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| EP2487159A1 (fr) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | Inhibiteurs du RORgammaT |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| KR101778354B1 (ko) | 2011-08-18 | 2017-09-13 | 니뽄 신야쿠 가부시키가이샤 | 헤테로환 유도체 및 의약 |
| WO2014026330A1 (fr) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | Composés 3-aminocycloalkyles en tant qu'inhibiteurs de rorgammat et leurs utilisations |
| WO2014026327A1 (fr) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | Composés d'acide benzoïque à substitution 4-hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations |
| WO2014026329A1 (fr) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | Composés d'indazole et d'indole n-alkylés en tant qu'inhibiteurs de rorgammat et leurs utilisations |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| CN103468812B (zh) * | 2013-09-17 | 2015-02-25 | 安徽医科大学 | 一种检测糖皮质激素治疗sle疗效的试剂盒 |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| EA201692111A1 (ru) | 2014-05-12 | 2017-08-31 | Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| JP2018510135A (ja) | 2015-02-11 | 2018-04-12 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用 |
| CN104774950B (zh) * | 2015-04-21 | 2017-10-03 | 安徽医科大学 | 一种基于hsp90aa1基因型预测糖皮质激素治疗sle疗效的试剂盒 |
| AU2016344111A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
| CA3002850A1 (fr) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Composes indazole substitues utilises en tant qu'inhibiteurs de rorgammat et utilisations associees |
| CN110452203B (zh) * | 2019-08-29 | 2021-04-13 | 忻州师范学院 | 一种1-氧代-1,3-二氢-3-羟基苯并呋喃-5-甲酸的制备方法 |
| EP4125919A1 (fr) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Inhibiteurs de cathepsine pour la prévention ou le traitement d'infections virales |
| AU2023232562A1 (en) | 2022-03-08 | 2024-09-05 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB607839A (en) | 1946-02-12 | 1948-09-06 | Bristol Aeroplane Co Ltd | Improvements in or relating to gas-turbine power-plants |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| EP0633776B1 (fr) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Composes destines a traiter les maladies allergiques et inflammatoires |
| AU679511B2 (en) | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
| CA2192668A1 (fr) | 1994-06-15 | 1995-12-21 | Harold Francis Hodson | Derives d'amidinosulfones a utiliser comme allegations d'inhibiteurs inos |
| SI0820279T1 (en) | 1995-04-14 | 2002-12-31 | Smithkline Beecham Corporation | Metered dose inhaler for albuterol |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| ES2224628T3 (es) | 1998-03-14 | 2005-03-01 | Altana Pharma Ag | Inhibidores de pde iii/iv a base de ftalazinonas. |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| DE19856475A1 (de) * | 1998-11-27 | 2000-05-31 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| CA2371273A1 (fr) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Composes modulateurs de recepteur de progesterone tetracycliques et procedes |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| BRPI0113042B8 (pt) | 2000-08-05 | 2021-05-25 | Glaxo Group Ltd | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato |
| BR0114323A (pt) | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| BR0209271A (pt) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
| US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| USRE44874E1 (en) | 2001-09-14 | 2014-04-29 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| WO2003037352A1 (fr) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles utiles comme inhibiteurs de cyclooxygenase pour le traitement de troubles associes a l'inflammation |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| CA2472746A1 (fr) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations |
| EP1467730A4 (fr) | 2002-01-22 | 2010-03-10 | Univ California | Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| CN1633296A (zh) | 2002-03-26 | 2005-06-29 | 贝林格尔·英格海姆药物公司 | 糖皮质素模拟物、其制备方法、药物组合物及其用途 |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| CA2481320A1 (fr) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide |
| AU2003222841A1 (en) | 2002-04-25 | 2003-11-10 | Glaxo Group Limited | Phenethanolamine derivatives |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1521733B1 (fr) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulateurs du recepteur glucocorticoide |
| WO2004009017A2 (fr) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulateurs de recepteurs de glucocorticoides et procede associe |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| JP2006504678A (ja) | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| ES2331119T3 (es) | 2002-09-16 | 2009-12-22 | Glaxo Group Limited | Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa. |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| ES2291733T3 (es) | 2002-10-22 | 2008-03-01 | Glaxo Group Limited | Compuestos de ariletanolamina medicinales. |
| SI1556342T1 (sl) | 2002-10-28 | 2008-08-31 | Glaxo Group Ltd | Fenetanolaminski derivat za zdravljenje respiratornih bolezni |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| WO2004071389A2 (fr) * | 2003-02-15 | 2004-08-26 | Glaxo Group Limited | Composés |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| UY28526A1 (es) * | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
| PL1677795T3 (pl) | 2003-10-14 | 2011-05-31 | Glaxo Group Ltd | Antagoniści receptora muskarynowego acetylocholiny |
| CN1901958B (zh) | 2003-11-03 | 2011-03-09 | 葛兰素集团有限公司 | 流体分配装置 |
| AR046225A1 (es) | 2003-11-04 | 2005-11-30 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion |
| TWI363759B (en) | 2004-04-27 | 2012-05-11 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| WO2006000398A1 (fr) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Derives de 2,3-benzoxazine utilises en tant que modulateurs non steroidiens du recepteur glucocorticoide |
| WO2006000401A1 (fr) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Oxazines substituees utilisees comme modulateurs du recepteur glucocorticoide |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| ES2367515T3 (es) | 2004-10-19 | 2011-11-04 | F. Hoffmann-La Roche Ag | Derivados de quinolina. |
| US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| EP1869003B1 (fr) * | 2005-04-14 | 2013-05-15 | Glaxo Group Limited | Indazoles en tant que ligands de recepteur glucocorticoide |
| GB0513297D0 (en) * | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| GB0611587D0 (en) * | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| WO2008000777A2 (fr) * | 2006-06-29 | 2008-01-03 | Glaxo Group Limited | Nouveaux composés |
-
2006
- 2006-06-12 GB GBGB0611587.7A patent/GB0611587D0/en not_active Ceased
-
2007
- 2007-06-11 ES ES07765362T patent/ES2355165T3/es active Active
- 2007-06-11 PT PT07765362T patent/PT2029549E/pt unknown
- 2007-06-11 EA EA200802322A patent/EA015540B1/ru not_active IP Right Cessation
- 2007-06-11 TW TW096121030A patent/TW200815360A/zh unknown
- 2007-06-11 WO PCT/EP2007/055724 patent/WO2007144327A2/fr active Application Filing
- 2007-06-11 DK DK07765362.4T patent/DK2029549T3/da active
- 2007-06-11 SI SI200730484T patent/SI2029549T1/sl unknown
- 2007-06-11 AU AU2007260067A patent/AU2007260067B2/en active Active
- 2007-06-11 MX MX2008015977A patent/MX2008015977A/es active IP Right Grant
- 2007-06-11 BR BRPI0713755A patent/BRPI0713755A8/pt not_active Application Discontinuation
- 2007-06-11 US US12/303,791 patent/US8247377B2/en active Active
- 2007-06-11 KR KR1020097000591A patent/KR101411276B1/ko active IP Right Grant
- 2007-06-11 PL PL07765362T patent/PL2029549T3/pl unknown
- 2007-06-11 CN CN2007800295932A patent/CN101501003B/zh active Active
- 2007-06-11 CA CA2659564A patent/CA2659564C/fr active Active
- 2007-06-11 DE DE602007010456T patent/DE602007010456D1/de active Active
- 2007-06-11 JP JP2009514772A patent/JP5497433B2/ja active Active
- 2007-06-11 AT AT07765362T patent/ATE487703T1/de active
- 2007-06-11 EP EP07765362A patent/EP2029549B1/fr active Active
- 2007-06-11 AR ARP070102547A patent/AR061341A1/es unknown
-
2008
- 2008-11-25 IL IL195492A patent/IL195492A0/en unknown
- 2008-11-28 ZA ZA200810161A patent/ZA200810161B/xx unknown
- 2008-12-08 NO NO20085100A patent/NO20085100L/no not_active Application Discontinuation
- 2008-12-10 CR CR10489A patent/CR10489A/es not_active Application Discontinuation
- 2008-12-12 MA MA31473A patent/MA30514B1/fr unknown
-
2009
- 2009-07-22 HK HK09106729.6A patent/HK1127609A1/xx unknown
-
2011
- 2011-02-02 CY CY20111100112T patent/CY1111454T1/el unknown
- 2011-02-08 HR HR20110097T patent/HRP20110097T1/hr unknown
-
2012
- 2012-07-13 US US13/548,573 patent/US20120277279A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110097T1 (hr) | Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora | |
| JP5809704B2 (ja) | ＪＡＫ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体およびイミダゾ［４，５−ｂ］ピリジン誘導体 | |
| US20210275522A1 (en) | Pharmaceutical compositions and use thereof | |
| HRP20100573T1 (hr) | Triazolopiridinkarboksamidni derivati, njihovo dobivanje i njihova upotreba u terapiji | |
| JP2014037426A5 (fr) | ||
| MX347706B (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
| WO2017040993A4 (fr) | Petites molécules inhibitrices de dyrk1a et leurs utilisations | |
| HRP20171795T1 (hr) | Dvojni selektivni inhibitori pi3 delta i gamma kinaze | |
| JP2016513717A5 (fr) | ||
| JP2006503048A5 (fr) | ||
| CA3091339A1 (fr) | Inhibiteurs de la voie jak1 pour le traitement de troubles lies aux cytokines | |
| US11414413B2 (en) | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof | |
| ES2932049T3 (es) | Compuestos heterocíclicos para el tratamiento de enfermedades | |
| CA2679198A1 (fr) | Composes heterocycliques utiles dans le traitement de maladies et de conditions | |
| US20240158347A1 (en) | Psychotropic agents and uses thereof | |
| JP2010510202A5 (fr) | ||
| HRP20181027T1 (hr) | Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a | |
| JP2022507251A (ja) | Ｐ２ｘ３調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用 | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| RU2013125488A (ru) | Производное транс-2-деценовой кислоты и содержащее его фармацевтическое средство | |
| RU2011147208A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ccr3 | |
| HRP20110624T1 (hr) | Supstituirani piperazinilpirazini kao antagonisti receptora 5-ht7 | |
| KR20060086942A (ko) | Ｐ2ｘ7 수용체 길항제 및 비스테로이드성 소염 약물을포함하는 제약 조성물 | |
| AR058199A1 (es) | Derivados de 3- alquilazetidina sustituidos con heterociclos | |
| JP2010513489A5 (fr) |